tbuckley/cabot-search huggingface dataset:
Beta1 integrin-mediated adhesion between renal tubular cells after anoxic injury.
Authors: W Lieberthal, J B McKenney, C R Kiefer, L M Snyder, V M Kroshian, M D Sjaastad
Journal: Journal of the American Society of Nephrology (1997)

beta 1 integrin-mediated adhesion between renal tubular cells after anoxic injury. This study examined the effect of sublethal injury, induced by ATP depletion (5 mM cyanide in the absence of dextrose), on the distribution and function of beta 1 integrins in primary cultures of mouse proximal tubular (MPT) cells. It was shown in this study that sublethal injury results in loss of focal contacts present in uninjured MPT cells, and that the beta 1 integrin molecule becomes redistributed to the apical membrane domain of sublethally injured cells. Polystyrene beads coated with Arg-Gly-Asp (RGD)-containing peptide adhere to the surface of sublethally injured MPT cells but not to control, dextrose-treated cells, indicating that the beta 1 integrins present on the apical surface of the cell remain functional. The presence of an excess of free RGD-containing peptide reduces binding of RGD-coated beads to sublethally injured MPT cells by approximately 50%. It was also demonstrated that adherence of MPT cells in suspension to cyanide-treated monolayers is increased more than 300% above adhesion to control, uninjured monolayers. This abnormal cell-cell adhesion is ameliorated by the presence of an excess of RGD-containing peptide and is reversed if cyanide-treated cells are allowed to recover for 1 h. It was concluded that the beta 1 integrin becomes expressed on the apical surface of MPT cells after sublethal injury. These apically expressed integrins remain functional and mediate aberrant adhesion between MPT cells.
A comparison between treatment outcomes of stage III and stage IV esophageal squamous cell carcinoma without visceral or bone metastases
Authors: Y. Wang, D. Liu, B. Chang, R. Kao, Y. Lai, W. Hsu
Journal: Journal of Clinical Oncology (2009)

e15659 Background: Although classified as end-stage, patients of stage IV esophageal squamous cell carcinoma (SCC) without visceral or bone metastases (nodal stage IV) often have good performance status and are medically fit for curative treatment. The objective of this study was to compare the prognosis of patients of stage III and nodal stage IV. Methods: The retrospective study included patients who were diagnosed esophageal squamous cell carcinoma at Tzu Chi General Hospital from Jan, 2005 to Aug, 2008. Eligible patients must meet the following criteria: (1) stage III or nodal stage IV; (2) underwent esophagectomy or chemoradiation with curative intent; (3) Eastern Cooperative Oncology Group performance status ≤2. The standard order-set of chemotherapy was two monthly cycles of fluorouracil (1,000 mg/m2/24 hours for 4 days) and cisplatin (75 mg/m2 bolus day 1). Radiotherapy dose was 59.4 Gy for concurrent chemoradiation (CCRT) or 54 Gy for adjuvant setting after esophagectomy. Results: Patients characteristics were listed in Table . The median follow-up was 8 months (range: 1∼42 months). In 38 patients underwent definitive CCRT, ten achieved complete response (CR) and 13 achieved partial response. Two-year disease-free survival rate in 28 patients who achieved CR or underwent esophagectomy was 29.9%. Median survival of stage III and nodal IV were 11.5 and 8 months. Two-year overall survival (OS) rate of stage III and nodal IV were 23.9% and 33% (p=0.814). The only significant poor prognostic factor in both univariate and multivariate analyses was tumor length longer than 5 cm. Conclusions: In our study, medically fit patients of nodal stage IV esophageal SCC could achieve OS similar to those of stage III after intensive treatment. The result may indicate the necessity of developing a selection criterion in deciding which nodal stage IV patient should undergo curative treatment. [Table: see text] No significant financial relationships to disclose.
Anxiety levels modifies thoracoabdominal mechanics in asthmatic patients
Authors: Milene Saccomani, Denise Paisani, Karen Evaristo, Alberto Cukier, Rafael Stelmach, Celso Carvalho
Journal: European Respiratory Journal (2013)

Psychiatric disorders such as anxiety and depression are common in patients with moderate and severe asthma and focus of various treatments; however, it remains unknown if these disorders modify respiratory mechanics.  Objective : Investigate the influence of anxiety in the thoracoabdominal mechanics of patients with moderate or severe asthma.  Methods : Twenty nine patients were enrolled, 16 with symptoms of anxiety (GA, 46±12 yrs, BMI=28.2±5.1kg/m2) and 13 without symptom (GN, 49± 10 yrs, BMI =28.6±4.1kg/m2). All patients were evaluated by the Hospital Anxiety and Depression Scale and thoracoabdominal kinematics (total chest wall, upper, lower ribcage and abdominal volumes) was measured by optoelectronic plethysmography. Student9s t-test was used and significance level was set at 5%.  Results : Total chest wall volume was similar between the groups during quiet (GN=410±120 vs. GA= 340±90 mL; p>0.05) and deep breathing (GN=1430±370 vs. GA=1420±410; p Conclusion : Anxiety modifies thoracoabdominal mechanics and promotes a lower abdominal volume during quiet and deep breath in asthmatics patients. No change was observed in thoracic volumes between both groups.
The efficacy of non-myeloablative allogeneic stem cell transplantation in ZAP-70 positive/chemo-antibody refractory patients with chronic lymphocytic leukemia (CLL)
Authors: I. F. Khouri, M. J. Keating, R. M. Saliba, S. O’brien, R. E. Champlin, C. Bueso-Ramos
Journal: Journal of Clinical Oncology (2005)

6559 Background and Purpose: In aggressive CLL, the presence of an unmutated IgVH gene is strongly associated with the expression of ZAP-70. We used immunohistochemical techniques and routinely fixed, paraffin-embedded tissue to survey ZAP-70 expression in chemo-refractory patients with CLL who received a non-myeloablative allogeneic transplantation (NMT). Methods: The methodology for the ZAP-70 immunostaining was previously described (Modem Pathology 17:954, 2004). Tissues were scored in evenly labeled areas. All cases were reviewed by two authors. Nuclear staining of non-neoplastic, reactive T cells served as an internal control in each case. Neoplasms demonstrating nuclear staining in greater than 20% of tumor cells were considered positive. Patients were eligible for NMT if they have failed chemo-antibody combination of therapy. The conditioning regimens consisted of fludarabine, cyclophosphamide and rituximab (Blood 98:3595, 2001). Results: Twenty five consecutive pts were treated. ZAP-70 information was available for 22. Median age of these 22 pts was 54 yrs (range, 36–73), and 16 (73%) were males. Median time from diagnosis to NMT was 69 mos. Median # of prior chemoregimens received was 4. Ten (45%) had a B2-microglobulin level of >3, and 7 (32%) had evidence of large cell transformation. Seventeen of the 22 pts (77%) tested positively for ZAP-70 and five were negative. All 22 pts had evidence of active disease prior NMT by morphological examination as well as by flow cytometry. With a median follow-up time of 20 months, overall survival at 2-years was 63% and 80% for the ZAP (+) and the ZAP(-) groups, respectively (P=0.6). Patients with ZAP(+) and who had evidence of large cell transformation faired worse: only 2 of 6 pts (33%) were alive at 9+, and 18+ mos; whereas 10 of 11 pts (91%) who were ZAP(+) but with no evidence of transformation remained alive at a median of 23+ mos post NMT (range, 7+ to 45+ mos) (P = 0.001). Conclusions: These data suggest that NMT may overcome the negative prognostic impact of ZAP-positivity in CLL, and that transplantation should be considered earlier in the course of the disease, prior to large cell transformation. No significant financial relationships to disclose.
Inconclusive Results of Randomized Trials of Prenatal Vitamin D for Asthma Prevention in Offspring
Authors: Erika von Mutius, Fernando D. Martinez
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fine Structure and C19-Steroid Metabolism of Spontaneous Adenocarcinoma of the Canine Prostate2
Authors: I. Leav, L. F. Cavazos, P. Ofner
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Fine Structure and C19-Steroid Metabolism of Spontaneous Adenocarcinoma of the Canine Prostate Get access I. Leav, I. Leav 4 3Steroid Biochemistry Laboratory of the Medical Services, Lemuel Shattuck Hospital, Department of Public Health of the Commonwealth of Massachusetts, Boston, Mass. 02130; Department of Pathology, Angell Memorial Animal Hospital, Boston, Mass. 02115; and Department of Pathology, Tufts University School of Medicine, Boston, Mass. 02111. 4Address reprint requests to: Dr. Irwin Leav, Steroid Biochemistry Laboratory, Lemuel Shattuck Hospital, 170 Morton Street, Boston, Mass. 02130. Search for other works by this author on: Oxford Academic PubMed Google Scholar L. F. Cavazos, L. F. Cavazos 5Department of Anatomy, Tufts University School of Medicine, Boston, Mass. 02111. Search for other works by this author on: Oxford Academic PubMed Google Scholar P. Ofner P. Ofner Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 3, March 1974, Pages 789–804, https://doi.org/10.1093/jnci/52.3.789 Published: 01 March 1974 Article history Received: 06 August 1973 Accepted: 29 October 1973 Published: 01 March 1974
Regional Cooperation of Oral Care in Cancer Patients Between Tenpaku-Ku Dental Association and Nagoya Memorial Hospital
Authors: Kenji Ina, Satoshi Kayukawa, Miki Iwasaki, Ryuichi Furuta, Satoshi Hibi, Megumi Kabeya, Yuuko Sirokawa, Chiaki Koga, Takae Kataoka
Journal: Annals of Oncology (2014)
Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line
Authors: K Nason-Burchenal, D Gandini, M Botto, J Allopenna, JR Seale, NC Cross, JM Goldman, E Dmitrovsky, PP Pandolfi
Journal: Blood (1996)
Modified ECF/wPELF in advanced gastric cancer. Results of a phase II trial
Authors: F. Fochessati, D. Tassinari, V. Arcangeli, L. Gianni, M. Papi, A. Polselli, B. Poggi, M. Fantini, G. Genestreti, A. Ravaioli
Journal: Journal of Clinical Oncology (2004)

4170 Background. Although ECF represents the treatment of choice in advanced gastric cancer, weekly PELF (wPELF) may be considered an interesting alternative schedule in such a subset of patients. We present activity and safety data of a modified-ECF/alternating wPELF, in which a 21-day ECF was alternated with 6 courses of wPELF in advanced gastric cancer. Methods. All the patients with advanced or relapsed gastric cancer were considered eligible and enrolled into the trial. All the patients were treated with cisplatin 60mg/mq on day 1, epidoxorubicin 50mg/mq on day 1 and 5FU 200mg/mq on day 1→21, followed by 6 courses of weekly cisplatin 25mg/mq, epidoxorubicin 10mg/mq, etoposide 40mg/mq, and 24-hours infusion of l-folinic acid 120mg/mq and 5FU 2200mg/mq until progression of the disease or intractable toxicity. G-CSF support was used during wPELF. Results. 29 patients were considered eligible and enrolled into the trial. 22 patients (75.8%) presented a measurable, metastatic disease, and 7 patients (24.2%) an valuable, but not-measurable disease. After a median follow up of 10 months 3 complete responses (10.4%), 6 partial responses (20.7%) and 9 stable diseases (34.4%) were observed, with a median time to progression of 257 days. Till today 22 patients (75.9%) were dead, with a median survival of 229 days and 18 (62%), 15 (51.7%) and 12 (41.4%) patients alive respectively after 6, 9 and 12 months of follow up. Toxicity was mild, with grade III leucopenia in 6 patients (20.7%), grade III-IV neutropenia in 15 patients (51.7%), grade III vomiting in 3 patients (10.3%), grade III diarrhoea in 1 patient (3.4%), grade III mucositis in 1 patient (3.4%). No febrile neutropenia, nor haemorrhagic thrombocitopenia occurred in any patient. Conclusions. The addition of wPELF to ECF seems to add nothing in terms of activity against metastatic gastric cancer; otherwise the high effectiveness in terms of median survival and 1-year survival rate, with the interesting safety make the modified ECF/wPELF an interesting option as first line treatment of gastric cancer for further phase III trials. (Supported by IOR) No significant financial relationships to disclose.
Abstract P279: Trends in Treatment and Control of Vascular Risk Factors in U.S. Stroke Survivors: Results from the National Health and Nutrition Examination Surveys (NHANES), 1999-2008
Authors: Nilay S Shah, Mark D Huffman, Hongyan Ning, Donald M Lloyd-Jones
Journal: Circulation (2012)

Introduction: Treatment and control of vascular risk factors reduce the likelihood of recurrent stroke in stroke survivors. Current nationally-representative data are sparse regarding prevention treatment and control rates. Methods: We evaluated rates of blood pressure, cholesterol, and dysglycemia treatment and control (to goal levels) in a weighted sample of 936 adult stroke survivors using data from five consecutive two-year NHANES cycles, 1999 to 2008. We used weighted linear regression to estimate time trends. Results: The Figure shows sex-specific trends in mean systolic and diastolic blood pressure, total and HDL cholesterol, glucose, and hemoglobin A1c from 1999 to 2008. All measures remained unchanged over the study period, except for a decrease in mean (SE) systolic blood pressure in women from 142 (3.4) to 131 (1.9) mmHg, and total cholesterol in men from 5.4 (0.2) to 4.6 (0.2) mmol/L (p &lt; 0.05 for both). Blood pressure treatment rates did not change in either sex, but control rates increased in women from 23% (11 of 38) in 1999–2000 to 59% (50 of 93) in 2007–2008 (p = 0.03). Cholesterol treatment rates increased in women from 28% (19 of 73) to 34% (51 of 127) (p = 0.01) without increases in control to goal levels. In contrast, cholesterol control rates increased in men from 62% (17 of 23) to 78% (40 of 50) (p = 0.01). Dysglycemia treatment rates decreased in women from 20% (18 of 73) to 10% (15 of 127) (p = 0.02) but not in men, and control rates did not significantly change in either sex. Anti-platelet medication use also increased from 24% (36 of 157) to 34% (84 of 241) (p = 0.05). Conclusions: Despite improvements in blood pressure and cholesterol control rates in women and men, respectively, stroke secondary prevention through treatment and control of vascular risk factors remains substantially sub-optimal. Urgent action is needed to identify and close these gaps to reduce stroke morbidity and mortality in this high-risk group.
Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, &amp; NCCTG
Authors: M. L. Citron, D. A. Berry, C. Cirrincione, R. B. Livingston, W. Gradishar, E. Perez, H. Muss, L. Norton, E. Winer, C. Hudis
Journal: Journal of Clinical Oncology (2005)

620 Background: C9741 demonstrated superior DFS and OS for q14 day A, T, and C compared to q21 day treatment and no difference in outcomes with concurrent vs. sequential A and C. (J Clin Oncol 21:1431–39. 2003) Study design: Arm S3: Ax4 ->Tx4->Cx4 q3 weeks; Arm S2 (DD): Ax4->Tx4->Cx4 q2 weeks with filgrastim; Arm C3: ACx4->Tx4 q3 weeks; Arm C2 (DD): ACx4->Tx4 q2 weeks with filgrastim; A=doxorubicin 60mg/m2, T=paclitaxel 175 mg/m2 over 3 hours, and C=cyclophosphamide 600mg/m2. Red cell transfusion was observed in 13% of the first 412 patients (3,973 treatment cycles) with C2, compared to less than 4% in S2 and C3, and zero in S3. This observation prompted a more detailed review of the toxicity data. Methods: We performed a retrospective review of hemoglobin per course, use of epoetin alpha and transfusions. Use of epoetin alpha and transfusions were at discretion of physician. Time-to-event distributions were estimated by the Kaplan-Meier technique; two or more such distributions were compared with the logrank test. Chi-square tests compared two or more proportions; Results: Grade 2 anemia (hemoglobin < 10g/dL) was more frequent in C2, AC->T q 2 weeks. On treatment, 23% of C2 had ≥ Grade 2 anemia compared to 3% (S3), 11% (S-2) and 8% (C-3), P<0.0001. At cycle 5, C2 had the lowest nadir hemoglobin of 10.7 g/dL, 0.9 g/dL lower than the other arms. Epoetin alpha use was highest in C2 (11%) compared to S2 (5%), C3 (7%) and S3 (1%), with significantly greater epoetin alpha use at course 5, P=0.013. Conclusions: Dose-dense AC->T q14 days in C2 is associated with a greater incidence of moderate anemia, higher use of epoetin alpha and more red cell transfusions than the other arms. Red cell growth factors should be considered to reduce the severity of anemia. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, Bristol-Myers Squibb, Genentech Amgen, Bristol-Myers Squibb, Genentech Amgen, Bristol-Myers Squibb, Bristol
Prognosis of Nonprivate Cancer Patients&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Leslie Lipworth, M.B., B.Ch., Barbara Bennett, A.B., Paul Parker, Ed.D.
Journal: JNCI Journal of the National Cancer Institute (1972)

A study of cancer patients in Boston showed that, for 13 of 15 male and female cancer sites, patients in private institutions had higher survival rates than patients at free institutions by the end of the 2d and 4th months after diagnosis. By the end of the 10th month, the private patients had higher rates for all 15 sites. Further investigations also indicated more deaths within 20 days of surgery among the nonpaying cancer patients. The implications of these findings with regard to further study and the establishment of a peer review are discussed.
Phase II feasibility of concurrent docetaxel and post mastectomy radiation after four cycles of AC chemotherapy in patients with high risk operable breast cancer: A trial of the Cancer Research Group Pakistan
Authors: I. H. Shah, A. Shaharyar, A. Shahid, M. Hafeez, S. Perveen, A. Jameel, K. Shabbir, I. Randhawa, J. A. Gilani, A. I. Masood, A. A. Javed
Journal: Journal of Clinical Oncology (2006)

10684 Background: Sequential use of docetaxel after four cycles of AC chemotherapy delays the postoperative radiation and can compromise loco-regional control. This delay can be avoided by starting radiotherapy concurrent with the docetaxel. We evaluated the feasibility of concurrent docetaxel and radiation therapy to chest wall and peripheral lymphatics after four cycles of AC chemotherapy. The preliminary results were reported in ASCO 2005 (Abstract 858). Methods: Females between 18–50 years, T2-T3 lesions, four or more positive nodes and hormone receptor negative tumors were eligible. Patients were enrolled after MRM. Four cycles of AC at 60/600 mg/m 2 were followed by four cycles of docetaxel at 75mg/m 2 every 21-days. Concurrent radiation to chest wall and peripheral lymphatics was started with the third cycle of docetaxel. A dose of 50 Gy in 5 weeks or equivalent was delivered. Successful completion of treatment in 18 out of 20 or 25 out of 30 patients was chosen as an index of feasibility. CTC version 2.0 of NCI and RTOG/EORTC Late Radiation Morbidity Scoring Scheme was used. Results: All the 30 enrolled patients successfully completed the planned treatment. Radiation was completed within 6 months of surgery in 27(90%) of the patients. Febrile neutropenia was seen in 5(16.7%). Grade-3 neutropenia and diarrhea in 8(26.7%) and 6(20%) respectively. Grade-3 dermatitis in the radiated area was seen in 2(6.7%) and grade-2 in 5(16.7%). Late toxicity included grade-2 skin atrophy and telangiectasia in radiated area in 6(20%) each. At a median follow up of 20 months (range 9–25 months) two local recurrences and two systemic relapses have been seen. Conclusion: This treatment schedule is feasible and safe in patients with high-risk operable breast cancer. It allows delivery of post mastectomy radiation within 6 months of surgery in patients undergoing sequential AC-docetaxel chemotherapy. No significant financial relationships to disclose.
Primary Mammary Tumors Connected to the Host by a Single Artery and Vein
Authors: Flora H. Grantham, Donald M. Hill, Pietro M. Gullino
Journal: JNCI Journal of the National Cancer Institute (1973)

Primary tumors originating in the intermediate inguinal mammary glands of female Buffalo rats were surgically “isolated” from the surrounding tissues, so that one artery and one vein were the only connection between host and tumor. The vein of this tumor was cannulated in situ and tumor blood was collected for several hours. The primary tumor was also removed from the host and perfused as an isolated, intact organ.
연구논문 : 간경변증 쥐 모델에서 혈청 Hyaluronic acid와 간섬유화의 정량적 측정치 간의 상관관계
Authors: 김문영 ( Moon Young Kim ), 백순구 ( Soon Koo Baik ), 장윤옥 ( Yoon Ok Jang ), 석기태 ( Ki Tae Suk ), 김재우 ( Jae Woo Kim ), 김현수 ( Hyun Soo Kim ), 조미연 ( Mi Yun Cho ), 최선주 ( Sun Joo Choi ), 엄순호 ( Soon Ho Um ), 한광협 ( Kwang Hyub Han )
Journal: Clinical and Molecular Hepatology (2008)
S-phase fraction in node-negative breast cancer.
Authors: D E Merkel
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.6.1091 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2033424 S-phase fraction in node-negative breast cancer. D E MerkelxD E MerkelSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.6.1091 PDF "S-phase fraction in node-negative breast cancer.." Journal of Clinical Oncology, 9(6), pp. 1091–1092© 1991 by American Society of Clinical Oncology